About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

NAD: Novartis's Excedrin Ads Are Misleading; It Mostly Doesn't Work in "15 Minutes or Less"

By Jim Edwards | Mar 18, 2009

Wyeth has forced Novartis into a corner regarding advertising for Novartis’s Extra-Strength Excedrin. Novartis had been advertising Excedrin with the line, “Start relieving your headache in just 15 minutes.”

Wyeth, not believing that claim, challenged Novartis to prove it in a hearing at the National Division of Advertising, a sort of industry advertising police body. Here’s what the NAD said:

NAD determined that the plain language of the advertiser’s “start(s) relieving your headache in 15 minutes” claim expressly conveys the straightforward message that the average consumer can reasonably expect to start to feel some relief from headache pain within fifteen minutes of taking Extra Strength Excedrin.

NAD examined evidence that included a study provided by the advertiser on subjects who took either Extra Strength Excedrin or a placebo. NAD determined that the evidence demonstrated that while some consumers may feel some relief in fifteen minutes, most consumers will not experience perceptible relief in that short of a time period.

Ouch! Score one for Wyeth (which makes rival Advil, by the way). NAD asked Novartis to modify its ads, perhaps with the statement, “Some people will experience some relief in as a little as 15 minutes.” (I’ll bet the agency copywriters at Saatchi & Saatchi loved that idea.)

Novartis isn’t backing down:

Novartis respectfully disagrees with the NAD’s decision as to how consumers interpret its express claim ‘Start relieving your headache in just fifteen minutes.’

The company will appeal the decision to the National Advertising Review Board. If Novartis gets no joy there, the next stop could be the FTC.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • NAD Blasts Excedrin's Ad Claims

    Adweek - 250 days 20 hours 22 minutes ago

    NEW YORK The marketing industry's self-governing body has decided that Extra-Strength Excedrin's claim about headache relief within 15 minutes has no merit and is asking the brand to "modify or discontinue" the assertion.Today's ruling by the National Advertising Division, a unit of the Better Business Bureau, was prompted by a complaint from...

  • Around the Net In Brand Marketing: NAD: Excedrin's Claim Of 15-Minute Headache Relief Is Hooey

    MediaPost - 249 days 12 hours 13 minutes ago

    The National Advertising Division says that Extra-Strength Excedrin's claim about headache relief within 15 minutes has no merit, and it is asking the brand to "modify or discontinue" the assertion. The ruling was prompted by a complaint from Wyeth, a rival of Excedrin parent company Novartis, which claimed that a study Novartis submitted to...

  • Danes Police Baltic Airspace

    Aviation Week - 313 days 13 hours 44 minutes ago

    Since 5 January, Danish F-16s have been policing Baltic airspace from Siauliai, Lithuania. Four Danish air force F-16s, supported by 50 personnel, on 4 January relieved four U.S. Air Force F-15Cs which had been conducting the mission since October.     The aircraft are on 15-minute quick reaction alert for NATO's interim air policing of the...

  • YouTube Excedrin Challenge

    Adotas - 334 days 11 hours 9 minutes ago

    ADOTAS — With healthcare seeming to be a top priority in Obama’s incoming administration, pharmacutical companies and health providers need a way to engage with more people. Heaving regulation and concerns over privacy has stymied the effort online, though I know advertising agencies and companies are searching for the right campaigns....

  • Benefiber Ad Claims OK Per NAD

    Natural Products - 243 days 13 hours 27 minutes ago

    NEW YORK--Novartis Consumer Health Inc. has adequate substantiation for the advertising claims for its Benefiber dietary supplement, according to the National Advertising Division (NAD) of the Council of Better Business Bureaus (BBB). NAD opened the inquiry following a challenge by Procter & Gamble (P&G), makers of the Metamucil product line....

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    marketingsean

    03/19/09 | Report as spam

    RE: NAD: Novartis's Excedrin Ads Are Misleading; It Mostly Doesn't Work in

    what about the fact that Excedrin migraine - identical in composition to Excedrin - is marketed as a targeted solution to migraine pains, when in fact, it is identical to the product being marketed for headaches generally I suppose we see this frequently in other forms, but it begs the question of where do we draw the line on dishonesty?

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement